151751-Najiba-Chargi

224 CHAPTER 12 Table 1. (Continued) Low SMM Without low SMM n 68 (74.7%) 23 (25.3%) n (%) or mean(±SD) n (%) or mean(±SD) p-value a Alcohol abuse No Yes, current Yes, former 40 (58.8%) 6 (8.8%) 22 (81.5%) 17 (73.9%) 1 (4.3%) 5 (21.7%) 0.44 ACE-27 Score b None Mild Moderate Severe 6 (8.8%) 17 (25.0%) 25 (36.8%) 20 (29.4%) 2 (8.7%) 6 (26.1%) 8 (34.8%) 7 (30.4%) 1.0 Tumor Site Oropharynx Hypopharynx Larynx Other 48 (70.6%) 8 (11.8%) 2 (2.9%) 10 (14.7%) 17 (73.9%) 1 (4.3%) 2 (8.7%) 3 (13.1%) 0.73 TNM-stage Stage 1 Stage 2 Stage 3 Stage 4 1 (1.5%) 2 (2.9%) 8 (11.8%) 57 (83.8%) 0 (0.0%) 1 (4.3%) 5 (21.7%) 17 (73.9%) 0.62 Surgery No Yes 64 (94.1%) 4 (5.9%) 22 (95.7%) 1 (4.3%) 0.63 Recurrence No Yes 46 (67.6%) 22 (32.4%) 20 (87.0%) 3 (13.0%) 0.06 Synchronous tumor No Yes 56 (82.4%) 12 (17.6%) 20 (87.0%) 3(13.0%) 0.75 HPV status c Negative Positive Missing 44 (64.7%) 7 (10.3%) 17 (25.0%) 12 (52.2%) 6 (26.1%) 5 (21.7%) 0.21 a Chi-square test or Independent sample t-test, b ACE-27 = Adult Comorbidity Evaluation c HPV = Human Papillomavirus, ** Correlation is significant at the 0.01 level (2-tailed), * Correlation is significant at the 0.05 level (2-tailed) UNIVARIATE AND MULTIVARIATE ANALYSIS Table 2 shows the univariate and multivariate logistic regression analysis for the association with cetuximab DLT. In the univariate analysis, weight loss six months prior to diagnosis and ACE-27 score had statistically significant predictive value for cetuximab DLT. Low SMM did not show significant predictive value for cetuximab DLT (OR = 0.60; 95%CI 0.22-1.63; p = 0.31). The